In Brief: Beta carotene and lung cancer
This article was originally published in The Tan Sheet
Executive Summary
Beta carotene and lung cancer: FDA will evaluate current scientific evidence concerning the association of beta carotene and lung cancer and the public health risk, if any, associated with the marketing of dietary supplements containing beta carotene, the agency says in March 31 response to a July 1996 citizen petition from Victor Herbert, MD, Bronx V-A Medical Center. FDA denies Herbert's request that it issue regs mandating warning labels for supplements containing vitamins C or E. Herbert wanted warning labels stating: "Caution: The beta carotene in this product is synthetic and can promote cancer in smokers"; "Caution: The vitamin C in this product is synthetic and can promote the generation of harmful free radicals in the 12% of Americans with high body iron"; and "Caution: The vitamin E in this product is synthetic and prohemorrhagic and dangerous for people with a family history of hemorrhagic stroke"...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning